Publicaciones
-
Tanaka K, Adams B, Alvaro Madrid Aris, Fujita N, Ogawa M, Ortiz S, Vallee M and Greenbaum LA.
The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab
PEDIATRIC NEPHROLOGY . 36(4): 889-898. Nº de citas: 58
-
Gómez Delgado I, Corvillo F, Nozal P, Arjona E, Alvaro Madrid Aris, Melgosa M, Bravo J, Szilágyi Á, Csuka D, Veszeli N, Prohászka Z and Sánchez-Corral P.
Complement Genetic Variants and FH Desialylation in S. pneumoniae-Haemolytic Uraemic Syndrome.
Frontiers in Immunology . 12: 641656-641656. Nº de citas: 15
-
Melgosa M, Alvaro Madrid Aris, Alvárez O, Lumbreras J, Nieto F, Parada E, Perez-Beltrán V and Spanish Pediatric Nephrology Association.
SARS-CoV-2 infection in Spanish children with chronic kidney pathologies.
PEDIATRIC NEPHROLOGY . 35(8): 1521-1524. Nº de citas: 56
